All In Biotech

Drug Trial Radar · NCT07599670

A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of ABBV-1758 in Participants With Alzheimer's Disease

Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 210 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

210

Planned (sponsor's estimate)

Start

May 15, 2026

Primary completion

Oct 2030

Study completion Oct 2030

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
May 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population. Clinical symptoms of the disease may begin with occasional forgetfulness such as misplacement of items, forgetting important dates or events, and may progress to noticeable memory loss, increased confusion and agitation, and eventually, loss of independence and non-responsiveness. The purpose of this study is to test how safe ABBV-1758 is, how well it works, how the body processes it and what effects it has on the body. ABBV-1758 is an investigational drug being developed for the treatment of Alzheimer's disease. This study is conducted in 3 stages. Stage A is a multiple ascending dose study with a 1 in 5 chance (4:1 randomization) that participants are assigned to receive placebo. Stage B is a dose expansion phase, also using 4:1 randomization for ABBV-1758 or placebo. Stage C enrolls Japanese and Chinese participants with the same randomization scheme. Approximately 210 participants will be enrolled at about 55 sites in the United States, China, and Japan. Participants will receive intravenous (IV) or subcutaneous (SC) doses of ABBV-1758 or placebo once every 4 weeks (Q4W) for 24 weeks and will be followed for additional 12 weeks in the Follow-up Period. Participants will have the option of participating in a 12-month, blinded Extension Period receiving ABBV-1758 or placebo based on amyloid PET results. There may be higher treatment burden for participants in this trial compared to their standard of care due to study procedures. Participants will attend regular visits during the study at a hospital or clinic. The safety of the treatment will be checked by medical assessments, blood tests, and completing questionnaires.

Conditions

  • Alzheimer's Disease

Interventions

  • ABBV-1758Drug

    Intravenous (IV) or Subcutaneous (SC)

  • Placebo for ABBV-1758Drug

    Intravenous (IV) or Subcutaneous (SC)

  • ABBV-1758Drug

    Subcutaneous (SC)

  • Placebo for ABBV-1758Drug

    Subcutaneous (SC)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Experiencing Adverse Events (AEs)Time frame: Up to approximately 40 weeks
  2. Percentage of Participants with Abnormal Change from Baseline in Clinical Laboratory Test ResultsTime frame: Up to approximately 40 weeks
  3. Percentage of Participants With Amyloid-Related Imaging Abnormalities (ARIA)Time frame: Up to approximately 40 weeks
  4. Percentage of Participants with Abnormal Change From Baseline in Vital Sign MeasurementsTime frame: Up to approximately 40 weeks
  5. Percentage of Participants with Abnormal Change From Baseline in Electrocardiograms (ECGs) ParametersTime frame: Up to approximately 40 weeks
  6. Percentage of Participants Experiencing Any Suicidal Ideation or Suicidal Behavior As Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)Time frame: Up to approximately 40 weeks
  7. Stage A, B, and C: Change from Baseline in Brain Amyloid LoadTime frame: Up to approximately 28 Weeks
  8. Stage A and C: Maximum Plasma Concentration (Cmax) of ABBV-1758Time frame: Up to approximately 40 weeks
  9. Stage A and C: Time to Cmax (Tmax) of ABBV-1758Time frame: Up to approximately 40 weeks
  10. Stage A and C: Trough Concentration measured at the end of a dosing interval at steady state (Ctrough) of ABBV-1758Time frame: Up to approximately 40 weeks
  11. Stage A and C: Area under the Plasma Concentration-time Curve from Time Zero to the End of the Dosing Interval (AUCtau) of ABBV-1758Time frame: Up to approximately 40 weeks
  12. Stage A and C: Average Serum Concentration at Steady-State (Cav,ss) of ABBV-1758Time frame: Up to approximately 40 weeks
  13. Stage A and C: Accumulation ratio for (AUCtau) of ABBV-1758Time frame: Up to approximately 40 weeks
  14. Stage A and C: Total Body Clearance (CL) of ABBV-1758Time frame: Up to approximately 40 weeks
  15. Stage A and C: Apparent Clearance (CL/F) of ABBV-1758Time frame: Up to approximately 40 weeks
  16. Stage A and C: Volume of Distribution at Steady-State (Vss)Time frame: Up to approximately 40 weeks
  17. Stage A and C: Apparent Volume of Distribution during the Terminal Phase (Vz)Time frame: Up to approximately 40 weeks
  18. Stage A and C: Terminal Phase Elimination Rate Constant (β) of ABBV-1758Time frame: Up to approximately 40 weeks
  19. Stage A and C: Terminal Phase Elimination Half-Life (t1/2) of ABBV-1758Time frame: Up to approximately 40 weeks
  20. Stage A and C: Effective Half-Life (T1/2,eff)Time frame: Up to approximately 40 weeks

Locations

13 sites in 2 countries. Site status is shown where the registry gives one.

  • Irvine Center for Clinical Research /ID# 277752

    Irvine, California · Recruiting

  • Alpine Clinical Research Center - Boulder - 47th Street /ID# 277856

    Boulder, Colorado · Recruiting

  • Key Clinical Research LLC /ID# 277800

    Bradenton, Florida · Recruiting

  • K2 Medical Research - Clermont /ID# 277859

    Clermont, Florida · Recruiting

  • K2 Medical Research - The Villages /ID# 278290

    Lady Lake, Florida · Recruiting

  • Alzheimer'S Research And Treatment Center - Stuart /ID# 278206

    Stuart, Florida · Recruiting

  • Alzheimer's Research And Treatment Center - Wellington /ID# 277749

    Wellington, Florida · Recruiting

  • Conquest Research - Winter Park /ID# 277760

    Winter Park, Florida · Recruiting

  • Adams Clinical /ID# 277754

    Watertown, Massachusetts · Recruiting

  • Neurology Clinic - Cordova /ID# 277790

    Cordova, Tennessee · Recruiting

  • Kerwin Medical Center /ID# 277788

    Dallas, Texas · Recruiting

  • Xuanwu Hospital Capital Medical University /ID# 283310

    Beijing, Beijing Municipality, China · Recruiting

  • The Second Affiliated Hospital of Guangzhou Medical University /ID# 284295

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.